Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard ...

The drug is not considered a cure, but results from clinical trials point to major advancement for a devastating cancer ...

Investing.com -- Immuneering Corporation (NASDAQ:IMRX) stock fell 20% after hours Wednesday despite announcing positive ...

More than 67,000 Americans are expected to be diagnosed with pancreatic cancer this year, but a new blood test is offering ...

HUTCHMED has advanced its ongoing study of surufatinib and camrelizumab for treatment‑naïve metastatic pancreatic ductal ...

The American Cancer Society’s Report on the Status of Cancer Disparities in the United States examines disparities in cancer occurrence and outcomes, and analyzes the factors that contribute to these ...

Windsor resident beating the odds following devastating diagnosis and treatment for usually deadly form of pancreatic cancer.

A new study explains how pancreatic tumors use a sugar coating to hide from the immune system and shows that a newly ...

Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that reawakens the immune system ...

Final results from the phase 3 CASSANDRA trial presented at the 2025 ASCO Meeting show that the neoadjuvant chemotherapy ...